440 related articles for article (PubMed ID: 28228279)
1. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
George S; Miao D; Demetri GD; Adeegbe D; Rodig SJ; Shukla S; Lipschitz M; Amin-Mansour A; Raut CP; Carter SL; Hammerman P; Freeman GJ; Wu CJ; Ott PA; Wong KK; Van Allen EM
Immunity; 2017 Feb; 46(2):197-204. PubMed ID: 28228279
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Ben-Ami E; Barysauskas CM; Solomon S; Tahlil K; Malley R; Hohos M; Polson K; Loucks M; Severgnini M; Patel T; Cunningham A; Rodig SJ; Hodi FS; Morgan JA; Merriam P; Wagner AJ; Shapiro GI; George S
Cancer; 2017 Sep; 123(17):3285-3290. PubMed ID: 28440953
[TBL] [Abstract][Full Text] [Related]
3. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Zaretsky JM; Garcia-Diaz A; Shin DS; Escuin-Ordinas H; Hugo W; Hu-Lieskovan S; Torrejon DY; Abril-Rodriguez G; Sandoval S; Barthly L; Saco J; Homet Moreno B; Mezzadra R; Chmielowski B; Ruchalski K; Shintaku IP; Sanchez PJ; Puig-Saus C; Cherry G; Seja E; Kong X; Pang J; Berent-Maoz B; Comin-Anduix B; Graeber TG; Tumeh PC; Schumacher TN; Lo RS; Ribas A
N Engl J Med; 2016 Sep; 375(9):819-29. PubMed ID: 27433843
[TBL] [Abstract][Full Text] [Related]
4. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.
Trujillo JA; Luke JJ; Zha Y; Segal JP; Ritterhouse LL; Spranger S; Matijevich K; Gajewski TF
J Immunother Cancer; 2019 Nov; 7(1):295. PubMed ID: 31703593
[TBL] [Abstract][Full Text] [Related]
5. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Rizvi NA; Hellmann MD; Snyder A; Kvistborg P; Makarov V; Havel JJ; Lee W; Yuan J; Wong P; Ho TS; Miller ML; Rekhtman N; Moreira AL; Ibrahim F; Bruggeman C; Gasmi B; Zappasodi R; Maeda Y; Sander C; Garon EB; Merghoub T; Wolchok JD; Schumacher TN; Chan TA
Science; 2015 Apr; 348(6230):124-8. PubMed ID: 25765070
[TBL] [Abstract][Full Text] [Related]
11. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Hugo W; Zaretsky JM; Sun L; Song C; Moreno BH; Hu-Lieskovan S; Berent-Maoz B; Pang J; Chmielowski B; Cherry G; Seja E; Lomeli S; Kong X; Kelley MC; Sosman JA; Johnson DB; Ribas A; Lo RS
Cell; 2016 Mar; 165(1):35-44. PubMed ID: 26997480
[TBL] [Abstract][Full Text] [Related]
12. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Wang Q; Wu X
Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
[TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
14. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
[TBL] [Abstract][Full Text] [Related]
15. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
16. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
[TBL] [Abstract][Full Text] [Related]
17. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Ayers M; Lunceford J; Nebozhyn M; Murphy E; Loboda A; Kaufman DR; Albright A; Cheng JD; Kang SP; Shankaran V; Piha-Paul SA; Yearley J; Seiwert TY; Ribas A; McClanahan TK
J Clin Invest; 2017 Aug; 127(8):2930-2940. PubMed ID: 28650338
[TBL] [Abstract][Full Text] [Related]
18. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
[TBL] [Abstract][Full Text] [Related]
19. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab.
Cotangco K; Meram M; Lowe MP
J Natl Compr Canc Netw; 2020 Aug; 18(8):1012-1014. PubMed ID: 32755974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
